Stonepine Capital Management
Latest statistics and disclosures from Stonepine Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ADMA, EOLS, GLPG, JAZZ, RPRX, and represent 54.02% of Stonepine Capital Management's stock portfolio.
- Added to shares of these 10 stocks: JAZZ (+$6.1M), RPRX (+$6.0M), ZVRA, IRWD, VSTM, URGN, ESTA, ACAD, DAWN, INDV.
- Started 17 new stock positions in ARQT, KPRX, VSTM, DAWN, ITOS, RPRX, ZVRA, FNA, VIRX, URGN. INDV, MYO, Alimera Sciences Inc Cvr, JAZZ, TENX, ESTA, PYPD.
- Reduced shares in these 9 stocks: Alimera Sciences (-$20M), RVNC (-$10M), EOLS, AUPH, XOMA, Kiora Pharmaceuticals, MIST, ETON, GLPG.
- Sold out of its positions in Alimera Sciences, AUPH, ETON, Kiora Pharmaceuticals.
- Stonepine Capital Management was a net buyer of stock by $12M.
- Stonepine Capital Management has $158M in assets under management (AUM), dropping by 44.38%.
- Central Index Key (CIK): 0001440771
Tip: Access up to 7 years of quarterly data
Positions held by Stonepine Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Stonepine Capital Management
Stonepine Capital Management holds 38 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Adma Biologics (ADMA) | 23.6 | $37M | 1.9M | 19.99 |
|
|
| Evolus (EOLS) | 14.0 | $22M | -17% | 1.4M | 16.20 |
|
| Galapagos Nv Spon Adr (GLPG) | 8.7 | $14M | 479k | 28.79 |
|
|
| Jazz Pharmaceuticals Plc Us Listed Shs Usd (JAZZ) | 3.9 | $6.1M | NEW | 55k | 111.41 |
|
| Royalty Pharma Shs Class A (RPRX) | 3.8 | $6.0M | NEW | 212k | 28.29 |
|
| Xoma Corp Com New (XOMA) | 3.3 | $5.2M | -22% | 195k | 26.48 |
|
| Rigel Pharmaceuticals (RIGL) | 3.2 | $5.0M | 309k | 16.18 |
|
|
| Zevra Therapeutics Com New (ZVRA) | 3.1 | $4.9M | NEW | 700k | 6.94 |
|
| Anika Therapeutics (ANIK) | 3.0 | $4.7M | +14% | 189k | 24.70 |
|
| Revance Therapeutics (RVNC) | 2.7 | $4.3M | -70% | 820k | 5.19 |
|
| Ironwood Pharmaceuticals Com Cl A (IRWD) | 2.6 | $4.1M | +1982% | 1.0M | 4.12 |
|
| Verastem Com New (VSTM) | 2.5 | $3.9M | NEW | 1.3M | 2.99 |
|
| Optinose (OPTN) | 2.4 | $3.8M | +142% | 5.7M | 0.67 |
|
| Urogen Pharma (URGN) | 2.2 | $3.6M | NEW | 280k | 12.70 |
|
| Scpharmaceuticals (SCPH) | 2.2 | $3.6M | +84% | 779k | 4.56 |
|
| Establishment Labs Holdings Ord (ESTA) | 2.1 | $3.2M | NEW | 75k | 43.27 |
|
| ACADIA Pharmaceuticals (ACAD) | 1.9 | $3.0M | +3837% | 197k | 15.38 |
|
| Day One Biopharmaceuticals I (DAWN) | 1.8 | $2.9M | NEW | 206k | 13.93 |
|
| Aclaris Therapeutics (ACRS) | 1.8 | $2.8M | +27% | 2.5M | 1.15 |
|
| Tela Bio (TELA) | 1.8 | $2.8M | +77% | 1.1M | 2.53 |
|
| Indivior Ord (INDV) | 1.7 | $2.6M | NEW | 270k | 9.75 |
|
| Exagen (XGN) | 1.0 | $1.7M | +48% | 534k | 3.09 |
|
| Milestone Pharmaceuticals (MIST) | 1.0 | $1.5M | -19% | 1000k | 1.52 |
|
| Surrozen Com New (SRZN) | 0.8 | $1.3M | +66% | 110k | 11.98 |
|
| Aytu Biopharma (AYTU) | 0.7 | $1.2M | +6% | 501k | 2.35 |
|
| Kezar Life Sciences (KZR) | 0.7 | $1.2M | +41% | 1.5M | 0.77 |
|
| Adicet Bio (ACET) | 0.6 | $878k | 609k | 1.44 |
|
|
| Arcutis Biotherapeutics (ARQT) | 0.5 | $823k | NEW | 89k | 9.30 |
|
| Paragon 28 (FNA) | 0.5 | $766k | NEW | 115k | 6.68 |
|
| Kiora Pharmaceuticals (KPRX) | 0.5 | $741k | NEW | 202k | 3.66 |
|
| Polypid (PYPD) | 0.3 | $477k | NEW | 139k | 3.44 |
|
| 2seventy Bio Common Stock (TSVT) | 0.3 | $472k | 100k | 4.72 |
|
|
| Myomo Com New (MYO) | 0.3 | $401k | NEW | 100k | 4.01 |
|
| Aprea Therapeutics Com New (APRE) | 0.2 | $377k | 137k | 2.75 |
|
|
| Iteos Therapeutics (ITOS) | 0.2 | $306k | NEW | 30k | 10.21 |
|
| Tenax Therapeutics Com New (TENX) | 0.1 | $173k | NEW | 50k | 3.46 |
|
| Viracta Therapeutics (VIRX) | 0.1 | $116k | NEW | 500k | 0.23 |
|
| Alimera Sciences Inc Cvr Com New | 0.1 | $96k | NEW | 2.4M | 0.04 |
|
Past Filings by Stonepine Capital Management
SEC 13F filings are viewable for Stonepine Capital Management going back to 2015
- Stonepine Capital Management 2024 Q3 filed Nov. 13, 2024
- Stonepine Capital Management 2024 Q2 restated filed Aug. 21, 2024
- Stonepine Capital Management 2024 Q2 filed Aug. 13, 2024
- Stonepine Capital Management 2024 Q1 filed May 15, 2024
- Stonepine Capital Management 2023 Q4 filed Feb. 13, 2024
- Stonepine Capital Management 2023 Q3 filed Nov. 13, 2023
- Stonepine Capital Management 2023 Q2 amended filed Aug. 16, 2023
- Stonepine Capital Management 2023 Q2 filed Aug. 11, 2023
- Stonepine Capital Management 2023 Q1 filed May 12, 2023
- Stonepine Capital Management 2022 Q4 filed Feb. 14, 2023
- Stonepine Capital Management 2022 Q3 filed Nov. 10, 2022
- Stonepine Capital Management 2022 Q2 filed Aug. 12, 2022
- Stonepine Capital Management 2022 Q1 filed May 16, 2022
- Stonepine Capital Management 2021 Q4 filed Feb. 14, 2022
- Stonepine Capital Management 2021 Q3 filed Nov. 12, 2021
- Stonepine Capital Management 2021 Q2 restated filed Aug. 16, 2021